Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder
Wayne State University
Summary
This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.
Description
This study will use a double-blind, 10Hz left dlPFC rTMS (vs. sham) and pharmacological stressor (\[yohimbine + hydrocortisone\] vs. placebo) within-subject, randomized crossover design. Each participant will complete 4 sessions (stressor vs. placebo, crossed with rTMS vs. sham), each separated by at least 1 week. Participants will complete these 4 (2x2 within subject) test conditions in randomized order: sham rTMS/placebo stress, sham rTMS/active stress, active rTMS/ placebo stress, and active rTMS/active stress. The PI will perform randomization using a Latin Square and will assign particip…
Eligibility
- Age range
- 21–60 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Meet DSM-5 criteria for OUD; * Age 21-60 yr; * Right handed; * Males and non-pregnant/non-lactating females; * cognitively intact (total IQ score \>80 on Shipley Institute of Living Scale); * Screening cardiovascular indices within ranges for safe use of the pharmacological stressor: resting HR 50-90 bpm, systolic BP 90-140 mmHg, and diastolic BP 50-90 mmHg; * Use alcohol and/or marijuana \<3 times/week; each "time" should consist of \<1 marijuana "joint" equivalent and \<3 alcoholic drinks. Exclusion Criteria: * Under influence of any substance during session; * Past…
Interventions
- DrugYohimbine + Hydrocortisone
Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
- DeviceActive rTMS
10Hz rTMS over the left dlPFC
- DrugPlacebo
lactose (inside capsule)
- DeviceSham rTMS
inactive stimulation over the left dlPFC
Location
- Tolan Park Medical BuildingDetroit, Michigan